Journal Article

Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes

Guthrie, Susan, Hanney, Stephen, Montague, Erin, Pollitt, Alexandra, Glover, Matthew, Grant, Jonathan, Buxton, Martin

2018

Overview

Background Building on an approach applied to cardiovascular and cancer research, we estimated the economic returns from United Kingdom public- and charitable-funded musculoskeletal disease (MSD) research that arise from the net value of the improved health outcomes in the United Kingdom. Methods To calculate the economic returns from MSD-related research in the United Kingdom, we estimated (1) the public and charitable expenditure on MSD-related research in the United Kingdom between 1970 and 2013; (2) the net monetary benefit (NMB), derived from the health benefit in quality adjusted life years (QALYs) valued in monetary terms (using a base-case value of a QALY of £25,000) minus the cost of delivering that benefit, for a prioritised list of interventions from 1994 to 2013; (3) the proportion of NMB attributable to United Kingdom research; and (4) the elapsed time between research funding and health gain. The data collected from these four key elements were used to estimate the internal rate of return (IRR) from MSD-related research investments on health benefits. We analysed the uncertainties in the IRR estimate using a one-way sensitivity analysis. Results Expressed in 2013 prices, total expenditure on MSD-related research from 1970 to 2013 was £3.5 billion, and for the period used to estimate the rate of return, 1978-1997, was £1.4 billion. Over the period 1994–2013 the key interventions analysed produced 871,000 QALYs with a NMB of £16 billion, allowing for the net NHS costs resulting from them and valuing a QALY at £25,000. The proportion of benefit attributable to United Kingdom research was 30% and the elapsed time between funding and impact of MSD treatments was 16 years. Our best estimate of the IRR from MSD-related research was 7%, which is similar to the 9% for CVD and 10% for cancer research. Conclusions Our estimate of the IRR from the net health gain to public and charitable funding of MSD-related research in the United Kingdom is substantial, and justifies the research investments made between 1978 and 1997. We also demonstrated the applicability of the approach previously used in assessing the returns from cardiovascular and cancer research. Inevitably, with a study of this kind, there are a number of important assumptions and caveats that we highlight, and these can inform future research.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Biomedical Research - economics / Cancer / Cardiovascular diseases / Care and treatment / Charities / Cost-Benefit Analysis / Economic aspects / Financing, Government / Health Administration / Health Care Costs / Health Policy / Health Services Research / Humans / Medical research / Medical research charities / Medical research investment / Medicine / Medicine & Public Health / Medicine, Experimental / Musculoskeletal disease / Musculoskeletal Diseases - economics / Musculoskeletal Diseases - therapy / Public Health / QALYs / Quality-Adjusted Life Years / R & D/Technology Policy / Rate of return / Research grants / State Medicine / Translational Research, Biomedical - economics / Treatment Outcome / United Kingdom / Value of health